Gene Sequencing & Haplotyping
Whereas conventional approaches for targeted sequencing are hypothesis-driven, largely miss intronic genetic variation, and will fail to identify a large share of structural variants, the TLA technology enables hypothesis-neutral complete sequencing of any genomic locus.
TLA thus enables the identification of all genetic variation in loci of interest.
In addition, TLA enables haplotyping across large physical distances, both with short- and long-read sequencing technologies.
The TLA technology is highly flexible. Any genomic region of interest can be sequenced by simply using one primer pair complementary to a short locus-specific sequence.
"Targeted Locus Amplification (TLA), a comprehensive method of selectively amplifying genes and detecting all variation within, while preserving haplotype information.”
"Unlike other targeted sequencing methods, TLA works without detailed prior locus information, as one primer pair is sufficient to amplify and sequence tens to hundreds of kilobases of surrounding DNA.”Pacific Biosciences
- Application notes
Application note on the TLA protocol for isolated genomic DNA.
Application Note Pacific Biosciences - Targeted Sequencing and Chromosomal Haplotype Assembly Using Cergentis TLA Technology with PacBio SMRT Sequencing.
Cosemans N, et al. (2018)
University Hospital Leuven, Rady Children's Hospital & Leuven Autism Research
Rothammer S et al. (2018)
LMU Munich & The L.K. Ernst Institute of Animal Husbandry
Vermeulen C et al. (2017)
Cergentis, Hubrecht Institute-KNAW, Kariminejad-Najmabadi Pathology & Genetics Center, National and Kapodistrian University of Athens, Sara Medical Genetics Lab, Shahid Beheshti University of Medical Sciences, University Medical Center Utrecht & University of Patras
Van Schil et al. (2017)
Ghent University, Harvard Medical School, Seattle Children's Research Institute, The Children's Hospital of Philadelphia, University of Cologne, University of Tuebingen, University of Washington School of Medicine
Hottentot QP et al. (2016)
Cergentis & Leiden University Medical Center
Van der Werf IM et al. (2016)
Ghent University Hospital, Greenwood Genetic Center, Heinrich-Heine University, University Antwerpen & University Duisburg-Essen
Costa V et al. (2016)
Roche, Pvalue Research SRL, University of Basel, University Hospital Basel & University of Zurich
Snyder MW et al. (2015)
University of Washington, Oregon Health & Sciences University & University of Michigan
De Vree PJP et al. (2014)
Cergentis, Erasmus Medical Center, Ghent University, Hubrecht Institute-KNAW, Leiden University Medical Center, The Netherlands Cancer Institute, Radboud University Medical Center, University of Amsterdam, University of Groningen, University Medical Center Utrecht & VIB